Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Friedman

Showing results (1361-1370 of 1,475) with videos related to

Pageof 148
Sort By:
The Journal of Clinical Investigation|September 10, 2014
miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathwaysHui Wang, Tao Sun, Jing Hu, et al.
Advances in Radiation Oncology|June 1, 2022
Long-Term Outcomes for Patients With Atypical or Malignant Meningiomas Treated With or Without Radiation Therapy: A 25-Year Retrospective Analysis of a Single-Institution ExperienceCollin L Kent, Yvonne M Mowery, Olayode Babatunde, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2011
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastomaJames J Vredenburgh, Annick Desjardins, David A Reardon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Phase II trial of bevacizumab and irinotecan in recurrent malignant gliomaJames J Vredenburgh, Annick Desjardins, James E Herndon, et al.
Molecular Cancer Therapeutics|October 15, 2009
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiformeJohn H Sampson, Gary E Archer, Duane A Mitchell, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2026
Distinct neural processes link speech planning and executionSuseendrakumar Duraivel, Shervin Rahimpour, Katrina Barth, et al.
Journal of the Optical Society of America. A, Optics, Image Science, and Vision|January 5, 2001
Photometric observations of a polychromatic laser guide starR Foy, M Tallon, I Tallon-Bosc, et al.
JACC. Heart Failure|October 31, 2025
A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary HypertensionGyeongtae S Moon, Paul J Scheel, Maggie Montovano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant gliomaJill A Maxwell, Stewart P Johnson, Roger E McLendon, et al.
British Journal of Cancer|November 19, 2009
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II studyD A Reardon, A Desjardins, J J Vredenburgh, et al.
Pageof 148

Showing results (1361-1370 of 1,475) with videos related to

Sort By:
Pageof 148
The Journal of Clinical Investigation|September 10, 2014
miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathwaysHui Wang, Tao Sun, Jing Hu, et al.
Advances in Radiation Oncology|June 1, 2022
Long-Term Outcomes for Patients With Atypical or Malignant Meningiomas Treated With or Without Radiation Therapy: A 25-Year Retrospective Analysis of a Single-Institution ExperienceCollin L Kent, Yvonne M Mowery, Olayode Babatunde, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2011
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastomaJames J Vredenburgh, Annick Desjardins, David A Reardon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Phase II trial of bevacizumab and irinotecan in recurrent malignant gliomaJames J Vredenburgh, Annick Desjardins, James E Herndon, et al.
Molecular Cancer Therapeutics|October 15, 2009
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiformeJohn H Sampson, Gary E Archer, Duane A Mitchell, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2026
Distinct neural processes link speech planning and executionSuseendrakumar Duraivel, Shervin Rahimpour, Katrina Barth, et al.
Journal of the Optical Society of America. A, Optics, Image Science, and Vision|January 5, 2001
Photometric observations of a polychromatic laser guide starR Foy, M Tallon, I Tallon-Bosc, et al.
JACC. Heart Failure|October 31, 2025
A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary HypertensionGyeongtae S Moon, Paul J Scheel, Maggie Montovano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant gliomaJill A Maxwell, Stewart P Johnson, Roger E McLendon, et al.
British Journal of Cancer|November 19, 2009
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II studyD A Reardon, A Desjardins, J J Vredenburgh, et al.
Pageof 148